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of children aged 5-17 years old was obtained from the Medical Expenditure Panel
Survey (MEPS) for the year 2008.MEPS obtained information fromparents about the
health and sociodemographic characteristics of children. Logistic regression along
with descriptive statistics was performed to explain racial and ethnic disparities
among parent reported ADHD. Also, test for normality of residuals, homoscedas-
ticity, goodness of fit and model specification were performed. All analysis was
performed using STATA 11. RESULTS: Out of 6858 children between ages 5-17
years; parents reported ADHD for 633 (9.23%) children. Out of 6858 children 51%
were female, 34% were whites and 43% had any public insurance. Hispanic (OR
0.45 p0.000) and Black (OR0.77 p0.025) parents were less likely to report ADHD
than whites. Parents were more likely to report ADHD for Boys (OR0.65 p0.000),
children with age more than 10 yrs (OR1.85 p0.000), with private (OR1.37
p0.013) and public insurance (OR1.80 p0.012) and frommetropolitan statistical
area (OR 1.20 p0.116). CONCLUSIONS: There are racial disparities among parent
reported ADHD, whites are more likely to report ADHD than Hispanics and blacks.
These differences continue to exist even after controlling for child’s sociodemo-
graphic characteristics and other health related variables.
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OBJECTIVES: Individuals with bipolar disorder (BD) experience a high degree of
impairment that affects aspects of daily life including autonomy, relationships and
employment. The Wide AmbispectiVE study of the clinical management and bur-
den of bipolar disorder (WAVE-bd) aimed to describe functioning and quality of life
(QoL) in a multinational BD cohort. METHODS: Multinational, multicenter, non-
interventional, cohort study of patients diagnosedwith BD-I or BD-II with1mood
episode in the preceding 12 months (retrospective data collection) followed by a
minimum 9 months’ prospective follow-up. Functioning was measured using the
Functioning Assessment Short Test (FAST) tool (score range: 0-72, higher score
indicates worse functionality, results presented from initial visit). QoL was mea-
sured with the EuroQoL-5D visual analogue scale (VAS) tool (score range: 0-100,
higher score indicates better health), and the EQ-5D Index (score range: 0-1, higher
score indicates better health) at every visit during the study. RESULTS: Overall,
2,896 patients were included in the analysis (1,989 BD-I, 907 BD-II). FAST total
scores (meanSD) for BD-I and BD–II patients, respectively, were 50.117.2 and
48.816.5. QoL fluctuated with disease phase; in BD-I patients the EQ-5D VAS
scores (meanSD) were 71.918.3 in hypomania, 70.418.7 in euthymia, 69.622.8
in mania, 56.518.5 in mixed episodes, and 53.522.0 in depression. In BD-II pa-
tients, EQ-5D VAS scores were 72.118.7 in hypomania, 70.017.8 in euthymia and
54.220.2 in depression. EQ-5D Index scores (meanSD) reflected a similar trend
(BD-I: hypomania 0.700.28, mania 0.670.29, mixed episodes 0.530.28, depres-
sion 0.490.29, euthymia 0.410.27; BD-II: hypomania 0.650.27, depression
0.460.27, euthymia 0.410.26). CONCLUSIONS: Patients with BD-I and BD-II ex-
perienced a high level of functional impairment compared to healthy individuals.
QoL was similar in both BD-I and BD-II, and was lowest in patients experiencing
depressive andmixed episodes, and highest in hypomanic episodes and euthymia.
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OBJECTIVES:Major Depressive Disorder (MDD) has been cited as one of the leading
causes of disabilities worldwide. This analysis seeks to explore the prevalence of
MDD across select geographies and to compare the profile of sufferers.METHODS:
Data were taken from the US, Brazil, and Japan 2011 National Health andWellness
Survey, a cross-sectional Internet-based survey representative of the adult popu-
lation. Patients were classified as having MDD using the Patient Health Question-
naire (PHQ9). Health-related quality of life (HRQoL) was assessed with the SF-12
Health Survey (SF-12v2), and activity impairment was measured with the Work
Productivity andActivity Impairment questionnaire (WPAI). Comparisons between
patient groups were made with chi-square tests for categorical variables and
ANOVA for continuous variables. RESULTS: Prevalence of MDD differs significantly
across geographies, with Brazil having the highest percentage (9.8%, 13.5 M) fol-
lowed by US (7.1%, 16.2 M ) and Japan (4.7%, 5.0 M). In US and Brazil, MDD sufferers
were more likely to be women than non-sufferers and were significantly younger
(ps0.05). Sufferers in US, Brazil, and Japan were more likely to experience insom-
nia/sleep difficulties and anxiety than non-sufferers (p0.05). In each geography,
MDD sufferers had a significantly lower mental QoL compared to the non-sufferer
population, but the association was strongest in Japan (28.5 vs. 31.9 in the US vs.
35.4 in Brazil; p0.05). In US, MDD sufferers reported greater work and activity
impairment (42.0% and 51.3%, respectively vs. 12.2% and 18.2% for non-sufferers,
respectively; ps0.05). In all geographies, MDD sufferers had more ER visits in the
past six months relative to non-sufferers (p0.05) with the highest proportion in
Brazil (35.8%). Hospitalization among MDD sufferers was also highest in Brazil
(15.7%). CONCLUSIONS: Cross-country comparisons of MDD can provide insights
to themagnitude of the problem and assess disease burden among these sufferers.
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OBJECTIVES: The aim of this study was to assess the impact of positive and nega-
tive symptoms and cognitive impairment (CI) on health-related quality of life
(HRQOL), productivity loss and health care resource utilization (HCRU) in European
patients with schizophrenia. METHODS: An analysis of patient and physician-
reported data from the cross-sectional Adelphi Schizophrenia Disease-Specific-
Programme was conducted. Subjects 18 years or older with 4 physician visits in
the past year were selected (n2411). Patient-reported HRQOLwas assessed by the
Quality of Life Enjoyment and SatisfactionQuestionnaire-Short Form (Q-LES-Q-SF),
EQ-5D and EQ-5D Visual Analogue Scale (VAS) and work productivity via the Work
Productivity Activity and Impairment (WPAI). HCRU included number of outpa-
tient, emergency and inpatient visits and length of hospital stay (LOS). Analyses of
outcomes and utilization by level and severity of physician-rated positive, negative
and cognitive symptoms employedmultivariate methods (linear, logistic, negative
binomial, tobit and ordered probit regressions) with a backward selection process.
Age, gender, ethnicity, home circumstances, employment, number of comorbidi-
ties, anxiety, depression, non-drug therapy, substance abuse, obesity and medica-
tion compliance served as covariates. RESULTS: Most patients were older, male,
Caucasian, lived alone or with family and were unemployed. Positive symptoms
(delusions, disordered thoughts) and negative symptoms (blunted affect, social
withdrawal) were reported in 40-50% of the patients. Average severity scores for
positive and negative symptoms were 40 (max. 100, higher scores are more se-
vere). A total of 84% of patients suffered “mild” to “continuous or severe CI”. Mul-
tivariate analysis showed that the presence and severity of negative symptoms
decreased Q-LES-Q-SF and EQ-5D VAS scores. CI severity significantly predicted
HRQOL measures, productivity loss in terms of decreased ability to do regular
activities, outpatient, inpatient visits, LOS and non-drug therapy. CONCLUSIONS:
CI was uniquely associated with patient functioning and HCRU. Pharmacological
and non-pharmacological interventions targeted toward CIs may result in better
functioning and lower HCRU.
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OBJECTIVES: About 121 million people worldwide suffer from depression, and it is
the fourth leading cause of disability, according to the World Health Organization.
Cross-cultural studies have revealed that depressive disorders constitute a public
health problem inmost societies. This study is aimed to assess co-morbidity, qual-
ity of life (QOL), work/productivity loss, andmedical resource utilization in patients
diagnosed with depression in Brazil.METHODS: A total of 12,000 Individuals’ (age
18) self-reported data were collected from 2011 National Health and Wellness
Survey (NHWS) in Brazil.. QOL was measured by the physical component score
(PCS) and mental component score (MCS) of the Short Form-12 (SF-12). Loss of
work/productivity was measured by the validated Work Productivity and Activity
Impairment instrument. Medical resource utilization was measured by healthcare
provider, emergency room visits and hospitalization in the past 6 months.
RESULTS: Of the 12,000 respondents, 1,379 (10.8%) had been diagnosed with de-
pression, predominantly women (67.5%). Highest proportion of depression diag-
nosed patients was found between those 18-34 years old (40.8%). Those diagnosed
with depression reported more co-morbidities (anxiety 77.0%, headache 74.8%,
sleep difficulties 59.1%, insomnia 56.65%, pain 47.2%, migraine 39.6%), lower mean
scores of PCS (46.1 vs. 50.1) and MCS (35.8 vs. 48.3), more emergency room visits
(42.4% vs. 19.3%), and more patients being hospitalized for any medical condition
(19.7% vs. 8.6%) over the past 6months compared to not diagnosedwith depression
group. Furthermore, patients diagnosed with depression reported greater overall
work impairment (36.9% vs. 17.3%) and impairment in daily activity (44.5% vs.
18.3%) compared to patients not diagnosed with depression. All comparisons were
statistically significant at p 0.05. CONCLUSIONS: Results from the Brazil NHWS-
indicate patients diagnosedwith depression suffer from impairment in QOL, work/
productivity loss, greater usage of health care resources and more co-morbidities.
Findings indicate there is an unmet medical need in depressive patients in Brazil.
PMH60
HEALTH-RELATED QUALITY OF LIFE (HRQOL) AMONG SURVIVORS 8 MONTHS
AND 3 YEARS AFTER SICHUAN 2008 EARTHQUAKE IN CHINA
Ke X1, Chen Y2, Mock N3, Shi L3
1North Sichuan University, Nachong, Sichuan, China, 2Fudan University, Shanghai, Shanghai,
China, 3Tulane University, New Orleans, LA, USA
OBJECTIVES: To measure the impact of the catastrophic 2008 earthquake in the
Sichuan province of China on HRQOL among survivors.METHODS: The study em-
ployed a two-wave longitudinal study of survivors 8 months and three years after
the earthquake, using a probability cluster sample design stratified according to
three levels of earthquake impact. Twelve shelters out of nine townships were
selected during the first-wave sampling, which included three shelters out of three
severely affected townships, six shelters out of three moderately affected town-
ships, and three shelters out of three mildly affected townships. The study was
restricted to individuals between 16 and 89 years of age. A total of 1617 survivors
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returned the study survey. The SF-36 instrument was used to measure HRQOL and
comparedwith the provincial norm. The secondwavewas a random sample of 323
respondents from the initial 1617 first-wave respondents, who were interviewed
with an identical instrument 3 years after the earthquake. ANOVA and t-tests were
used to compare SF-36 scores among residents by earthquake impact levels;
against a provincial norm; and between 8months and 3 years. RESULTS: The SF-36
subscale scores differed by the impact level of earthquake except for RP. Compared
with the Sichuan provincial norm, all subscale SF-36 scores of the first-wave re-
spondents were lower atmonth 8 (all p-values0.001). Seven subscale scores of RP,
BP, GH, VT, SF, RE, and MH at 3 years were statistically lower than the provincial
norm (all p-values0.05). Among the second-wave respondents, all the 3-year
SF-36 subscale scores improved in comparison to those taken 8 months after the
earthquake except for RP and SF. CONCLUSIONS: The HRQOL declined compared
with the norm, especially the psychological aspects. Furthermore, the HRQOL 3
years after the earthquake were persistently lower than the norm level, despite its
recovery from 8-month level.
PMH61
EFFECTS OF LISDEXAMFETAMINE DIMESYLATE AUGMENTATION ON
FUNCTIONAL OUTCOMES IN ADULTS WITH PARTIALLY OR FULLY REMITTED
MAJOR DEPRESSIVE DISORDER
Supina D1, Endicott J2, Madhoo M1, Keefe RSE3, Trivedi M4, Wu J1, Scheckner B1,
Lasser R1
1Shire Development, LLC, Wayne, PA, USA, 2Columbia University; New York State Psychiatric
Institute, New York, NY, USA, 3Duke University Medical Center, Durham, NC, USA, 4University
of Texas Southwestern Medical School, Dallas, TX, USA
OBJECTIVES: In adults with executive dysfunction and mild major depressive dis-
order (MDD), lisdexamfetamine dimesylate (LDX) augmentation significantly im-
proved executive dysfunction (primary endpoint) on the Behavior Rating Inventory
of Executive Function–Adult Version (BRIEF-A). Because cognitive impairment can
affect functioning, including the ability to work, we describe LDX effects on func-
tional outcomes from the aforementioned study. METHODS: This double-blind,
placebo-controlled study enrolled participants (18–55 y)withmildMDD (Montgom-
ery-Åsberg Depression Rating Scale total score 18) and executive dysfunction
(BRIEF-A Global Executive Composite T-score60) on stable SSRI monotherapy for
8 weeks. After 2 weeks of screening, participants were randomized to 9 weeks of
double-blind LDX (week 1: 20 mg/d; weeks 2–6: maintain or increase LDX in 10-mg
increments weekly to 70 mg/d; weeks 7–9: maintain optimized dose) or placebo
augmentation, followed by 2 weeks of single-blind placebo. Prespecified secondary
functional endpoints included theQuality of Life Enjoyment and SatisfactionQues-
tionnaire (Q-LES-Q) and Endicott Work Productivity Scale (EWPS). Analyses in-
cluded analysis of covariance in randomized participants who took 1 study drug
dose and had 1 postbaseline BRIEF-A assessment. RESULTS: Of 143 randomized
participants (placebo, 72; LDX, 71), 119 completed double-blind treatment (placebo,
59; LDX, 60). For the Q-LES-Q, least squares (LS) mean (95% CI) treatment differ-
ences at endpoint significantly favored LDX in 5 of 10 domains: “physical health
activities” (9.6 [3.6, 15.6]; p0.0020), “feelings” (5.8 [0.0, 11.6]; p0.0481), “work” (9.1
[2.0, 16.1]; p0.0123), “household duties” (8.8 [2.2, 15.4]; p0.0094), and “general
activities” (6.2 [1.0, 11.4]; p0.0191); no differentiation was observed in the other
domains. For the EWPS, the LS mean (95% CI) treatment difference at endpoint
numerically favored LDX but was not statistically significant (–4.4 [–10.9, 2.0;
p0.1731). CONCLUSIONS: These findings suggest LDX augmentation modestly
improves functional outcomes in adults with partially or fully remitted MDD.
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OBJECTIVES: Schizophrenic patients often remain symptomaticwith predominant
(or persistent) negative symptoms (PNS) despite receiving antipsychotic therapy.
Negative symptoms might include social withdrawal, poverty of speech, apathy,
inability to experience pleasure, limited emotional expression, or defects in atten-
tion control. Several definitions of PNS exist. The purpose of this study is to de-
scribe PNS population according to several definitions. METHODS: Definitions of
patients with PNS were searched in literature, and applied to patients from the
EuroSC cohort (N288 in France, N618 in Germany andN302 in UK). Five assess-
ments including Positive and Negative Symptoms Scale (PANSS) were performed
over 2 years. The extent of overlap between definitions was assessed at baseline,
and pathways of patients with PNS were explored over 2 years. Bivariate analyses
were conducted to compare patients with PNS to others in terms of quality of life
(QoL), side effects, functioning and depression. RESULTS: Six definitions were
found, all based on PANSS subscores. Results differed according to countries, with
an average of 41% of patients with PNS in France, 24% in UK and 13% in Germany.
For all definitions, about 60% of patients with PNS at baseline still had PNS after 6
months, and about 40% still had PNS after 2 years. PNS patients were found to have
a lower QoL (EQ-5D: 0.70 vs. 0.74 on average), more severe side-effects (SAS: 4.2
vs.3.2 on average), lower functioning (GAF: 40 vs. 54 on average) and to be more
depressed (CDSS: 3.7 vs.2.6 on average). CONCLUSIONS: Our study suggests that
patients with PNS form a stable population overtime with higher clinical burden.
The lack of specific treatment pattern raises the issue of the need for specific
disease management strategy of patients with PNS. Further analyses on clinical
and economical burden of these patients are required.
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OBJECTIVES: Anxiety disorders represent the most common psychiatric illness in
the US Pharmacotherapy is the most common approach to treat anxiety disorders.
Our objective is to determine the extent to which patients with anxiety disorder
seek pharmacological treatment and to examine factors that are associated with
the pharmacological treatment utilization. METHODS: We evaluated Medical Ex-
penditures Panel Survey (MEPS) data (data pooled for survey calendar years 2005-
2009). Adult MEPS respondents (age17), identified as having anxiety disorder con-
dition (n  3412) were included in the study. Andersen behavioral model of health
services utilization was used as the conceptual framework for the study. Depen-
dent variables were defined as utilization of anti-anxiety medications (model A)
and number of prescriptions for anxiety disorders (model B). Independent vari-
ables, i.e. predisposing, enabling and need variables, were defined for each model
based on current literature and availability in MEPS. Logistic regression (model A)
and Poisson regression (model B) analyses were conducted to find the predictors of
medication utilization as well as the number of prescriptions. RESULTS: Sixty-one
percent of adults with anxiety disorder take anti-anxiety medication (95% CI: 59%,
63%). Formodel A, significant variables were race (Native Hawaiian/Pacific Islander
versus white, OR0.001, p0.001), education (no education versus elementary
school, OR 0.295, p0.039), prescription drug insurance coverage (no coverage
versus coverage for at least one round in year, OR 0.768, p 0.005), insurance
coverage (private insurance versus public insurance, OR 0.749, p 0.034), having
irritable bowel syndrome (IBS) (OR2.951, p0.016), andmood disorder (OR2.194,
p0.0001). For model B, significant variables were cost index (-0.391, p0.0001),
number of comorbidities (0.163, p0.0001) and age (-0.174, p 0.043).
CONCLUSIONS: Utilization rate of anti-anxiety medications among adult patients
with anxiety disorder is high. Demographic variables are less likely to affect this
utilization, while enabling and clinical need variables are highly influential.
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OBJECTIVES: To compare deviation rates from the labeled average daily consump-
tion (DACON) in patients with ADHD initiated on lisdexamfetamine dimesylate
(LDX) versus other once-daily FDA-approved stimulant medications. METHODS:
Patients with ADHD initiated on a stimulant medication on or after February 23,
2007 were selected from a large US claims database. Based on age and previous
treatment, patientswere classified into treatment-naïve or previously-treated chil-
dren/adolescents (6-17 years old), and adults (18 years old), respectively. Further-
more, based on the initiated medication, patients were classified into 4 cohorts:
LDX, methylphenidate HCl (OROS MPH), other methylphenidate/dexmethylpheni-
date HCl long acting (MPH LA), and amphetamine long acting (AMPH LA). DACON
was defined as the quantity of units supplied divided by the number of days of
supply in the 12-month study period. The proportion of patientswhodeviated from
the labeledDACON (ie, DACON1 pill/day) and the likelihood of deviation from the
labeled DACONwere compared across cohorts using chi-square tests andmultiple
logistic regression models, respectively. RESULTS: Across all subgroups, the pro-
portion of patients who deviated from the labeled DACONwas significantly higher
in each treatment cohort (range: 7.4%-29.4%) versus the LDX cohort (range: 2.9%-
9.9%) (all p0.001). After adjustments, uniformly across all subgroups, patients in
each treatment cohort were significantly more likely to deviate from the labeled
DACON versus LDX-treated patients. In children/adolescent groups, odds ratios
ranged from 2.6 to 3.7 and 2.9 to 4.1 in the previously-treated and the treatment-
naïve cohorts, respectively (all p0.001). In adult groups, odds ratios ranged from
2.1 to 4.0 and 2.1 to 4.1 in the previously-treated and the treatment-naïve cohorts,
respectively (all p0.001). CONCLUSIONS: Findings suggest that LDX-treated pa-
tients were more likely to adhere to the dosing regimen recommended in FDA
labels and were less likely to have a DACON 1 compared with patients treated
with other once-daily stimulant ADHD medications.
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OBJECTIVES: Significant increase in antidepressant use has been described over
the last two decades. To date, no study has compared trends in antidepressant use
in countries with different economic characteristics. TheOBJECTIVES were to de-
scribe and compare the growth of antidepressants use by pharmacologic class from
the late 1990s onward among 10 countries and the relation to the evolution of the
Gross Domestic Product (GDP), total health expenditures (HE) and the pharmaceu-
tical expenditures (PE) in each country.METHODS: Retrospective analysis of sales
data extracted from IMSHealth commercial database between 1999 and 2008 in US,
France, Germany, UK, Spain, Italy, Greece, Poland, Hungary and the Czech Repub-
lic. Description of antidepressant volume in Defined Daily Dose (DDD) per capita,
comparison of growth (% change between 1999 and 2008) and descriptive relation-
ship with % change in GPD, PE and HE. RESULTS: Antidepressant use increased
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